openPR Logo
Press release

Ankylosing spondylitis Market to Register Incremental Growth During Forecast Period (2024-2034), Asserts DelveInsight | Sunshine Guojian Pharma, Suzhou Zelgen Biopharma, Akeso, Biocad, Tasly Pharma

05-17-2024 06:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Ankylosing spondylitis Market to Register Incremental Growth

The Ankylosing spondylitis Market size was valued at USD 4200 Million in the year 2021 and the report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the 7MM.
The Ankylosing spondylitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.

DelveInsight's "Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ankylosing spondylitis Market Insights [https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Ankylosing spondylitis Market Report:

*
The Ankylosing spondylitis market size was valued at USD 4200 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In the United States, ankylosing spondylitis is almost undiagnosed in roughly 50% of cases because of its mild course

*
The total prevalent population of Ankylosing spondylitis in seven major markets is 2,282,664 in 2021. These cases are estimated to increase in the forecast period

*
Among EU5 countries, Italy had the highest number of diagnosed prevalent cases for AS (191,566 cases), while UK had the least cases (54,634) in 2021

*
Key Ankylosing spondylitis Companies: Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others

*
Key Ankylosing spondylitis Therapies: 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others

*
The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females

Ankylosing spondylitis Overview

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and eventually, fusion of the vertebrae. It belongs to a group of conditions called spondyloarthropathies, which primarily affect the spine and sacroiliac joints.

Get a Free sample for the Ankylosing spondylitis Market Report -

https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ankylosing spondylitis Market

The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Ankylosing spondylitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ankylosing spondylitis Epidemiology Segmentation:

The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Ankylosing spondylitis

*
Prevalent Cases of Ankylosing spondylitis by severity

*
Gender-specific Prevalence of Ankylosing spondylitis

*
Diagnosed Cases of Episodic and Chronic Ankylosing spondylitis

Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ Ankylosing spondylitis Epidemiological Insights [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Ankylosing spondylitis treatment, visit @ Ankylosing spondylitis Medications [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ankylosing spondylitis Therapies and Key Companies

*
608 Dose A: Sunshine Guojian Pharmaceutical

*
Jaktinib: Suzhou Zelgen Biopharmaceuticals

*
AK111: Akeso

*
BCD-085: Biocad

*
Jitongning tablets: Tasly Pharmaceutical

*
Golimumab: Hanyang University Seoul Hospital

*
Bimekizumab: UCB Biopharma SRL

*
Upadacitinib: AbbVie

*
Ixekizumab: Eli Lilly and Company

Ankylosing spondylitis Market Strengths

*
Certain initiatives have been taken by private and government organizations to raise awareness about the disease. The Spondylitis Association of America (SAA) began officially celebrating SpA Awareness Month in May.

*
There has been an increase in pharmaceutical companies' investment in the research and development of drugs.

Ankylosing spondylitis Market Opportunities

*
Several pharmaceutical key players have taken the initiative to meet the unmet needs of the Ankylosing Spondylitis market's present situation.

*
The prevalence of Ankylosing Spondylitis diagnosis codes more than doubled between 2006 and 2016; increase in prevalence creates a lucrative opportunity for the Ankylosing Spondylitis market.

Scope of the Ankylosing spondylitis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Ankylosing spondylitis Companies: Sunshine Guojian Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Akeso, Biocad, Tasly Pharmaceutical, Hanyang University Seoul Hospital, UCB Biopharma SRL, AbbVie, Eli Lilly and Company, and others

*
Key Ankylosing spondylitis Therapies: 608 Dose A, Jaktinib, AK111, BCD-085, Jitongning tablets, Golimumab, Bimekizumab, Upadacitinib, Ixekizumab, and others

*
Ankylosing spondylitis Therapeutic Assessment: Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies

*
Ankylosing spondylitis Market Dynamics: Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Ankylosing spondylitis Unmet Needs, KOL's views, Analyst's views, Ankylosing spondylitis Market Access and Reimbursement

Discover more about therapies set to grab major Ankylosing spondylitis market share @ Ankylosing spondylitis market forecast [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-as-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Ankylosing spondylitis Market Report Introduction

2. Executive Summary for Ankylosing spondylitis

3. SWOT analysis of Ankylosing spondylitis

4. Ankylosing spondylitis Patient Share (%) Overview at a Glance

5. Ankylosing spondylitis Market Overview at a Glance

6. Ankylosing spondylitis Disease Background and Overview

7. Ankylosing spondylitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ankylosing spondylitis

9. Ankylosing spondylitis Current Treatment and Medical Practices

10. Ankylosing spondylitis Unmet Needs

11. Ankylosing spondylitis Emerging Therapies

12. Ankylosing spondylitis Market Outlook

13. Country-Wise Ankylosing spondylitis Market Analysis (2020-2034)

14. Ankylosing spondylitis Market Access and Reimbursement of Therapies

15. Ankylosing spondylitis Market Drivers

16. Ankylosing spondylitis Market Barriers

17. Ankylosing spondylitis Appendix

18. Ankylosing spondylitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ankylosing-spondylitis-market-to-register-incremental-growth-during-forecast-period-20242034-asserts-delveinsight-sunshine-guojian-pharma-suzhou-zelgen-biopharma-akeso-biocad-tasly-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ankylosing spondylitis Market to Register Incremental Growth During Forecast Period (2024-2034), Asserts DelveInsight | Sunshine Guojian Pharma, Suzhou Zelgen Biopharma, Akeso, Biocad, Tasly Pharma here

News-ID: 3501929 • Views:

More Releases from ABNewswire

Eosinophilic Asthma Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight | OC000459, ANB020, Reslizumab, Dexpramipexole, KHK4563
Eosinophilic Asthma Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeli …
Eosinophilic Asthma companies are Cheisi Pharmaceuticals, Teva Pharmaceuticals, Arteria Therapeutics, GlaxsoSmithKline, Novartis, And many others. (Albany, USA) DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Eosinophilic Asthma, historical and forecasted epidemiology as well as the Eosinophilic Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Eosinophilic Asthma market report provides current treatment practices, emerging drugs, the
Sanfilippo Syndrome Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight | SLS-005, LYS-SAF302, Tralesinidase alfa (BMN-250), and others.
Sanfilippo Syndrome Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeli …
Sanfilippo Syndrome companies are Amgen Inc, Alkem Labs, LUPIN, Hope Pharmaceuticals, Sanifit, BSN medical, Sun Pharmaceutical Industries Ltd, Seelos Therapeutics, Lysogene, BioMarin Pharmaceutical, Cipla Inc, Mylan N.V. Teva Pharmaceutical Industries Ltd, and Zydus Cadila, and others. (Albany, USA) DelveInsight's "Sanfilippo Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Sanfilippo Syndrome, historical and forecasted epidemiology as well as the Sanfilippo Syndrome market trends in the United States,
Chronic Spontaneous Urticaria Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight | Rilzabrutinib, Remibrutinib, Benralizumab, Fenebrutinib, more
Chronic Spontaneous Urticaria Market Forecast 2032: FDA Approvals, Clinical Tria …
Chronic Spontaneous Urticaria companies are Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly, Mylan N. V., Bayer, Merck, Aurobindo Pharma, Hikma Pharmaceuticals, PLC, WOCKHARDT, AbbVie, Inc., Cipla Inc., Teva Pharmaceutical, Pfizer, Allergan, Lupin, LEO Pharma A/S, and Johnson & Johnson, among others. (New York, USA) DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Spontaneous Urticaria,
Top Realtor in South Jordan, UT, Excels in Transparency, Empowering Buyers with Knowledge
Top Realtor in South Jordan, UT, Excels in Transparency, Empowering Buyers with …
South Jordan, UT - In an era where transparency in real estate transactions is more valued than ever, Hyrum Rosquist stands out as a top Realtor in South Jordan, UT [https://www.abnewswire.com/pressreleases/top-real-estate-agent-in-south-jordan-ut-champions-an-educationfirst-approach-saving-clients-thousands_697057.html], for his unwavering commitment to honesty and clarity. At Rosquist Real Estate, the emphasis is on empowering buyers and sellers through education, ensuring they are fully informed and comfortable with every decision made throughout their real estate journey. Hyrum Rosquist's

All 5 Releases


More Releases for Ankylosing

Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/ Retail Pharmacy to Dominate the
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027. Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631 Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen
Ankylosing Spondylitis Treatment Market Research and Forecast 2020-2026
The global ankylosing spondylitis treatment market is projected to exhibit considerable growth during the forecast period (2020-2026). Ankylosing spondylitis is an inflammatory disease that leads to the fusion of some small bones of the spine (vertebrae) making the spine less flexible. The rising geriatric population is expected to be a major cause responsible for ankylosing spondylitis. The rising focus of the players operating in the ankylosing spondylitis market towards investment
Ankylosing Spondylitis Market Shares, Strategies and Forecast Worldwide, 2017 - …
Ankylosing spondylitis is a systemic inflammatory disease that primarily affects the spine. In ankylosing spondylitis, the joints, ligaments, and spine become inflamed. The inflammation leads to pain and stiffness in the lower back of the body and progress into the upper spine, neck, and chest. The joints and bones (vertebrae) fuse together eventually, causing the spine to become rigid and inflexible. Fused spine is called as bamboo spine as it
Ankylosing Spondylitis Treatment Market Pegged for Robust Expansion During 2015 …
Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a type of arthritis, in which spine bones grow or fuse together, causing the spine to become rigid. Symptoms of ankylosing spondylitis include pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.
Ankylosing Spondylitis Market : New Study Offers Insights for 2025
Ankylosing spondylitis is a systemic inflammatory disease that primarily affects the spine. In ankylosing spondylitis, the joints, ligaments, and spine become inflamed. The inflammation leads to pain and stiffness in the lower back of the body and progress into the upper spine, neck, and chest. The joints and bones (vertebrae) fuse together eventually, causing the spine to become rigid and inflexible. Fused spine is called as bamboo spine as it